Regorafenib inhibits kinases and cellular pathways involved in angiogenesis and tumor growth, such as the VEGFR1-3, FGFR1-2, c-KIT, PDGFRα/β, RET, and BRAF. The gene discussed is BRAF; the disease is neoplasm.